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Background
Traces of allergenic food represent a significant health risk
for persons who have an allergy to specific food. Knowl-
edge is missing on the different risk components and par-
ticularly on the link between presence of traces of
allergens in food, food consumption behaviours of allergic
sufferers and thresholds of reaction. Moreover, there is a
lack of risk-based guidance and operational tools of those
involved in allergen risk management, who are food indus-
tries, the allergic individuals and the food regulators.
Peanut is associated with the highest prevalence of food
allergy and is one of the food allergens that lead to the
most severe adverse effects.
Methods
MIRABEL program involves ANSES, INRA and AllergyVi-
gilance Network in order to deal with medical research,
dietary survey, chemical analysis, socio-economics and
applied mathematics. Each risk component will be investi-
gated to accurately characterize the risk of peanut allergy
and to test different risk management options. Accurate
data will be collected on clinical characteristics of peanut
allergic patients, thresholds of reactions, consumptions
and behaviours relating to peanut-containing products
(chocolate, cereals or biscuits, etc). Peanut presence will
be analyzed in the most consumed products. Methodolo-
gical developments in Bayesian statistics and probabilistic
modelling will be realized to be able to combine the
acquired data in an integrated risk quantification model. A
cost-benefits analysis for the stakeholders (food industry,
allergic individuals and regulators) will also be conducted
to anticipate impacts of new policies.
Results
The patient survey started in April 2012 with 83 allergists
in town offices and hospitals. To date, 450 medical ques-
tionnaires were filled by 40 allergists. For 120 patients
among 148 tested, oral diagnostics gave positive results.
The rate of complete dietary questionnaires filled by the
patients is of 50% for the paper and of 30% for the online
questionnaires. The age of the patients ranges from 2 to
39 years with a median of 9 years. From the first results,
the sampling plan for monitoring allergens in consumed
food by allergic sufferers was designed. It was observed
that 17% of consumed products were labelled as “may
contain peanut traces”. The products collection will be
conducted in January 2013.
Conclusion
The program aims to set an integrated and operational
framework for the allergic risk analysis, in order to
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